Twist Bioscience Corp (NASDAQ: TWST) stock surged 6.99% in the pre-market trading session on Monday, after the synthetic biology and genomics company reported better-than-expected financial results for the fiscal fourth quarter and full year 2024.

For the fiscal fourth quarter, Twist Bioscience reported a narrower loss of $0.59 per share, beating analyst estimates of a $0.70 loss per share. The company's revenue for the quarter grew 26.53% year-over-year to $84.71 million, surpassing the consensus estimate of $82.20 million.

The strong financial performance was driven by robust demand for Twist's synthetic DNA-based products and services across various industries, including healthcare, industrial chemicals, agriculture, and academic research. The company's proprietary DNA synthesis platform continues to gain traction, positioning Twist Bioscience as a leader in the rapidly growing synthetic biology market.